[{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"a1d113e7-45a5-46a1-8196-cf5276aa0389","acronym":"","url":"https://clinicaltrials.gov/study/NCT06045091","created_at":"2023-09-21T15:10:48.099Z","updated_at":"2024-07-02T16:35:36.398Z","phase":"Phase 1","brief_title":"To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL","source_id_and_acronym":"NCT06045091","lead_sponsor":"Hrain Biotechnology Co., Ltd.","biomarkers":" IL6 • GZMB • IL15","pipe":"","alterations":" ","tags":["IL6 • GZMB • IL15"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/04/2023","start_date":" 07/04/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2023-09-21"},{"id":"941edf4a-6b54-4d8a-9d5f-0ece5295def7","acronym":"Immuno-PRISM","url":"https://clinicaltrials.gov/study/NCT05469893","created_at":"2022-07-22T12:56:51.323Z","updated_at":"2024-07-02T16:35:41.515Z","phase":"Phase 2","brief_title":"Immuno-PRISM (PRecision Intervention Smoldering Myeloma)","source_id_and_acronym":"NCT05469893 - Immuno-PRISM","lead_sponsor":"Irene Ghobrial, MD","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr t(4;14) • Chr t(14;16)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • Tecvayli (teclistamab-cqyv)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/10/2022","start_date":" 08/10/2022","primary_txt":" Primary completion: 07/31/2030","primary_completion_date":" 07/31/2030","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2023-08-01"},{"id":"79a0f31c-c586-4cb3-b568-d3dd8b7f2a5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05932680","created_at":"2023-07-06T16:10:12.596Z","updated_at":"2024-07-02T16:35:41.763Z","phase":"Phase 2","brief_title":"Limited-duration Teclistamab","source_id_and_acronym":"NCT05932680","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecvayli (teclistamab-cqyv)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-07-27"},{"id":"84abb3e0-a296-47e4-a28b-656c5aed78ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05161598","created_at":"2021-12-17T17:31:09.556Z","updated_at":"2024-07-02T16:36:05.447Z","phase":"","brief_title":"Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)","source_id_and_acronym":"NCT05161598","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" XPO1","pipe":"","alterations":" ","tags":["XPO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecvayli (teclistamab-cqyv)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-08-16"}]